Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.

Launched by IRCCS SYNLAB SDN · Mar 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying long non-coding RNAs (lncRNAs) to see how they might help diagnose and understand the progression of a type of cancer called Acute Lymphoblastic Leukemia (ALL) that affects T-cells in children. LncRNAs are special molecules that don’t make proteins but can influence how genes are turned on or off, which is important in cancer development. Researchers believe that identifying specific lncRNAs could provide new ways to diagnose T-ALL and predict how well a patient might respond to treatment.

To participate in this trial, children aged 1 to 18 who have been diagnosed with T-ALL and have leukemic cells in their blood are eligible. If they join, they can expect to undergo tests that will help researchers learn more about the role of these lncRNAs in their illness. This study is currently recruiting, and it's important to note that children who choose not to participate or do not meet the age requirements will not be enrolled. The findings from this research could lead to better diagnostic tools and treatments for T-ALL in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a diagnosis of T-ALL 1-18 years aged of both sexes;
• • Presence of leukemic cells in peripheral blood of recruited patients.
• Exclusion Criteria:
• • Patients who refuse to participate in the study;
• • Patients not falling in the age group mentioned above